Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Mefford, Dwain ^a   Mefford, Joel A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ERBB2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CHROMOSOME 8P; GENE CLUSTER; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC REGULATION; IMMUNE RESPONSE; MICROARRAY ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION; STROMA CELL; BREAST TUMOR; CLUSTER ANALYSIS; COHORT ANALYSIS; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; SURVIVAL; SWEDEN; TUMOR GENE;

BREAST NEOPLASMS; CLUSTER ANALYSIS; COHORT STUDIES; CONSERVED SEQUENCE; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; STROMAL CELLS; SURVIVAL ANALYSIS; SWEDEN;

EID: 77955797139     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-482     Document Type: Article

References (106)

1. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999, 96(16):9212-9217. 10.1073/pnas.96.16.9212, 17759, 10430922.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
3. Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu Rev Pathol 2008, 3:67-97. 10.1146/annurev.pathmechdis.3.121806.151505, 18039137.
4. Geyer FC, Marchio C, Reis-Filho JS. The role of molecular analysis in breast cancer. Pathology 2009, 41(1):77-88. 10.1080/00313020802563536, 19089743.
5. Sorlie T. Introducing molecular subtyping of breast cancer into the clinic?. J Clin Oncol 2009, 27(8):1153-1154. 10.1200/JCO.2008.20.6276, 19204193.
6. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360(8):790-800. 10.1056/NEJMra0801289, 19228622.
7. Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J Biol 2008, 7(2):6. 10.1186/jbiol67, 2263121, 18304379.
8. Miller LD, Liu ET. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res 2007, 9(2):206. 10.1186/bcr1662, 1868923, 17397520.
9. Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey S. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences 2001, 98(19):10869.
10. McShane L, Radmacher M, Freidlin B, Yu R, Li M, Simon R. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. 2002, 18:1462-1469. Oxford Univ Press.
11. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 2006, 22(12):1540-1542. 10.1093/bioinformatics/btl117, 16595560.
12. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 2006, 11(8):868-877. 10.1634/theoncologist.11-8-868, 16951390.
13. Nowak G, Tibshirani R. Complementary hierarchical clustering. Biostatistics (Oxford, England) 2008, 9(3):467.
14. Hartigan J. Direct clustering of a data matrix. Journal of the American Statistical Association 1972, 123-129.
15. Hartigan JA. Clustering algorithms. 1975, New York,: Wiley.
16. Cheng Y, Church GM. Biclustering of expression data. Proc Int Conf Intell Syst Mol Biol 2000, 8:93-103.
17. Ben-Dor A, Chor B, Karp R, Yakhini Z. Discovering local structure in gene expression data: the order-preserving submatrix problem. Journal of Computational Biology 2003, 10(3-4):373-384. 10.1089/10665270360688075, 12935334.
18. Tanay A, Sharan R, Shamir R. Discovering statistically significant biclusters in gene expression data. Bioinformatics 2002, 18(Suppl 1):S136-S144.
19. Madeira S, Oliveira A. Biclustering algorithms for biological data analysis: a survey. IEEE Transactions on computational Biology and Bioinformatics 2004, 24-45. 10.1109/TCBB.2004.2, 17048406.
20. Tanay A, Sharan R, Shamir R. Biclustering algorithms: A survey. Handbook of computational molecular biology 2005, 9:26.21-26.17.
21. Garey M, Johnson D. Computers and Intractability: A Guide to the Theory of NP-Completeness. 1979, San Francisco: WH Freeman.
22. Everitt B, Landau S, Less M. Cluster Analysis. 2001, London: Arnold, 4.
23. Horvath S, Zhang B, Carlson M, Lu K, Zhu S, Felciano R, Laurance M, Zhao W, Qi S, Chen Z. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences 2006, 103(46):17402.
24. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
25. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102(38):13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
26. Saldanha AJ. Java Treeview--extensible visualization of microarray data. Bioinformatics 2004, 20(17):3246-3248. 10.1093/bioinformatics/bth349, 15180930.
27. de Hoon M, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004, 20(9):1453. 10.1093/bioinformatics/bth078, 14871861.
28. Pawitan Y, Bjohle J, Amler L, Borg A, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7(6):R953-R964. 10.1186/bcr1325, 16280042.
29. Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look M, Yang F, Talantov D, Timmermans M, Meijer-van Gelder M, Yu J. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. The Lancet 2005, 365(9460):671-679.
30. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13(11):3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
31. Gene expression omnibus (GEO) Gene expression omnibus (GEO)., http://www.ncbi.nlm.nih.gov/geo/
32. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743. Website companion for, 10.1073/pnas.0409462102, 15701700., http://microarray-pubs.stanford.edu/wound_NKI/
33. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2(2):E7. 10.1371/journal.pbio.0020007, 314300, 14737219.
34. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743. 10.1073/pnas.0409462102, 548329, 15701700.
35. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein D, Altman R. Missing value estimation methods for DNA microarrays. 2001, 17:520-525. Oxford Univ Press.
36. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences 2003, 100(14):8418-8423.
37. Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A, Martiat P, Fox S, Harris A, Liu E. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences 2003, 100(18):10393-10398.
38. Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J, Geneix J, Bachelart L, Finetti P, Koki A, et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004, 23(14):2564-2575. 10.1038/sj.onc.1207361, 14743203.
39. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-272. 10.1093/jnci/djj052, 16478745.
40. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005, 65(10):4059-4066. 10.1158/0008-5472.CAN-04-3953, 15899795.
41. Bay BH, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood) 2006, 231(9):1516-1521.
42. Yap X, Tan HY, Huang J, Lai Y, Yip GW, Tan PH, Bay BH. Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 2009, 217(4):563-570. 10.1002/path.2489, 19116991.
43. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 2006, 12(15):4533-4544. 10.1158/1078-0432.CCR-05-2339, 16899599.
44. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan C, Polyak K. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 2006, 66(8):4065-4078. 10.1158/0008-5472.CAN-05-4083, 16618726.
45. Hodgson JG, Chin K, Collins C, Gray JW. Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 2003, 78(3):337-345. 10.1023/A:1023085825042, 12755492.
46. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005, 21(3):389-395. 10.1152/physiolgenomics.00025.2005, 15769908.
47. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588, 15591335.
48. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007, 12(6):631-635. 10.1634/theoncologist.12-6-631, 17602054.
49. Wang KK, Liu N, Radulovich N, Wigle DA, Johnston MR, Shepherd FA, Minden MD, Tsao MS. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 2002, 21(49):7598-7604. 10.1038/sj.onc.1205953, 12386823.
50. Revillion F, Pawlowski V, Hornez L, Peyrat JP. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer 2000, 36(8):1038-1042. 10.1016/S0959-8049(00)00051-4, 10885609.
51. Valenti MT, Bertoldo F, Dalle Carbonare L, Azzarello G, Zenari S, Zanatta M, Balducci E, Vinante O, Lo Cascio V. The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?. BMC Cancer 2006, 6:49. 10.1186/1471-2407-6-49, 1473200, 16515701.
52. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7(6):R953-964. 10.1186/bcr1325, 1410752, 16280042.
53. Gao SY, Li EM, Cui L, Lu XF, Meng LY, Yuan HM, Xie JJ, Du ZP, Pang JX, Xu LY. Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem 2009, 284(12):7995-8004. 10.1074/jbc.M809734200, 2658093, 19164283.
54. Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H. High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol 2009, 15(16):2016-2019. 10.3748/wjg.15.2016, 2675094, 19399936.
55. Kobel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, et al. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 2006, 25(2):121-130. 10.1097/01.pgp.0000185410.39050.ac, 16633060.
56. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005, 7(3):R365-373. 10.1186/bcr1006, 1143558, 15987432.
57. Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y, Liu P, Song A, Gang C, Han Z, et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 2008, 261(1):55-63. 10.1016/j.canlet.2007.11.018, 18155831.
58. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007, 24(2):69-78. 10.1007/s10585-006-9050-x, 17370041.
59. Boulay P, Cotton M, Melancon P, Claing A. ARF1 controls the activation of the PI3K pathway to regulate EGF dependent growth and migration of breast cancer cells. Journal of Biological Chemistry 2008, M803603200v803603201, 2662303, 18990689.
60. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61(16):5979-5984.
61. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res 2007, 13(15 Pt 1):4415-4421. 10.1158/1078-0432.CCR-07-0122, 17671124.
62. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 2008, 61(3):327-332. 10.1136/jcp.2007.052431, 18037662.
63. Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 2009, 11(3):R40. 10.1186/bcr2327, 2716509, 19549328.
64. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122(1):33-43. 10.1016/j.cell.2005.05.008, 16009131.
65. Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. Mol Endocrinol 2006, 20(8):1707-1714. 10.1210/me.2005-0334, 16396959.
66. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25(28):3994-4008. 10.1038/sj.onc.1209415, 16491124.
67. Wolf I, Bose S, Williamson E, Miller C, Karlan B, Koeffler H. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. International journal of cancer 2007, 120(5).
68. Tomaru Y, Kondo S, Suzuki M, Hayashizaki Y. A comprehensive search for HNF-3alpha-regulated genes in mouse hepatoma cells by 60K cDNA microarray and chromatin immunoprecipitation/PCR analysis. Biochem Biophys Res Commun 2003, 310(2):667-674. 10.1016/j.bbrc.2003.08.148, 14521963.
69. Bi X, Jones T, Abbasi F, Lee H, Stultz B, Hursh DA, Mortin MA. Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells. Oncogene 2005, 24(56):8229-8239. 10.1038/sj.onc.1208962, 16103875.
70. Jung V, Kindich R, Kamradt J, Jung M, Muller M, Schulz WA, Engers R, Unteregger G, Stockle M, Zimmermann R, et al. Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol Cancer Res 2006, 4(3):169-176. 10.1158/1541-7786.MCR-05-0165, 16547154.
71. Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, Wu TD, Cavet G, Zhang Z, Chant J. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008, 47(6):530-542. 10.1002/gcc.20558, 18335499.
72. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Letessier A, Ginestier C, Monville F, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005, 3(12):655-667. 10.1158/1541-7786.MCR-05-0128, 16380503.
73. Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, Elvin P, Cassidy A, Graham A, Spraggon C, Desille Y, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. Cancer Res 2005, 65(4):1376-1383. 10.1158/0008-5472.CAN-04-2706, 15735024.
74. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 2006, 66(24):11632-11643. 10.1158/0008-5472.CAN-06-2946, 17178857.
75. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, Vallot C, Pierron G, Radvanyi F, Delattre O. Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. Cancer Research 2008, 68(17):7165. 10.1158/0008-5472.CAN-08-1360, 18757432.
76. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006, 66(9):4636-4644. 10.1158/0008-5472.CAN-06-0031, 16651414.
77. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239. 10.1186/1471-2164-9-239, 2423197, 18498629.
78. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009, 11(2):R15. 10.1186/bcr2234, 2688939, 19272155.
79. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68(13):5405-5413. 10.1158/0008-5472.CAN-07-5206, 18593943.
80. Calabro A, Beissbarth T, Kuner R, Stojanov M, Benner A, Asslaber M, Ploner F, Zatloukal K, Samonigg H, Poustka A, et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 2009, 116(1):69-77. 10.1007/s10549-008-0105-3, 18592372.
81. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14(5):518-527. 10.1038/nm1764, 18438415.
82. Buess M, Nuyten DS, Hastie T, Nielsen T, Pesich R, Brown PO. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol 2007, 8(9):R191. 10.1186/gb-2007-8-9-r191, 2375029, 17868458.
83. Rønnov-Jessen L, Bissell M. Breast cancer by proxy: can the microenvironment be both the cause and consequence?. Trends in Molecular Medicine 2009, 15(1):5-13. 10.1016/j.molmed.2008.11.001, 2746030, 19091631.
84. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005, 3(6):e187. 10.1371/journal.pbio.0030187, 1088973,1088973, 15869330.
85. West RB, van de Rijn M. Experimental approaches to the study of cancer-stroma interactions: recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest 2007, 87(10):967-970. 10.1038/labinvest.3700666, 17700561.
86. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 2008, 88(6):591-601. 10.1038/labinvest.2008.31, 18414401.
87. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009, 15(3):778-787. 10.1158/1078-0432.CCR-08-1283, 19188147.
88. Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, Shao ZM. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 2006, 25(54):7201-7211. 10.1038/sj.onc.1209703, 16785997.
89. Xu L, Ashkenazi A, Chaudhuri A. Duffy antigen/receptor for chemokines (DARC) attenuates angiogenesis by causing senescence in endothelial cells. Angiogenesis 2007, 10(4):307-318. 10.1007/s10456-007-9084-y, 17955335.
90. Bandyopadhyay S, Zhan R, Chaudhuri A, Watabe M, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006, 12(8):933-938. 10.1038/nm1444, 16862154.
91. Iiizumi M, Bandyopadhyay S, Watabe K. Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression. Cancer Res 2007, 67(4):1411-1414. 10.1158/0008-5472.CAN-06-3801, 17308076.
92. Zijlstra A, Quigley JP. The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel. Cancer Cell 2006, 10(3):177-178. 10.1016/j.ccr.2006.08.012, 16959609.
93. Miller L, Mason S, Clyde D, McGinniss M. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. 1976, 295:302-304.
94. Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 2006, 20(1):59-64. 10.1096/fj.05-4764com, 16394268.
95. Grann V, Ziv E, Joseph C, Neugut A, Wei Y, Jacobson J, Horwitz M, Bowman N, Beckmann K, Hershman D. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. British Journal of Haematology 2008, 143(2):288. 10.1111/j.1365-2141.2008.07335.x, 2655355, 18710383.
96. Levy P, Ripoche H, Laurendeau I, Lazar V, Ortonne N, Parfait B, Leroy K, Wechsler J, Salmon I, Wolkenstein P, et al. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007, 13(2 Pt 1):398-407. 10.1158/1078-0432.CCR-06-0182, 17202312.
97. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6(1):17-32. 10.1016/j.ccr.2004.06.010, 15261139.
98. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008, 13(5):394-406. 10.1016/j.ccr.2008.03.007, 18455123.
99. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59(19):5002-5011.
100. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray J, Carey L, Richardson A, Weinberg R. Reconstruction of functionally normal and malignant human breast tissues in mice. Proceedings of the National Academy of Sciences 2004, 101(14):4966-4971.
101. Bissell M, Radisky D. Putting tumours in context. Nature Reviews Cancer 2001, 1(1):46-54. 10.1038/35094059, 11900251.
102. Langley R, Fidler I. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocrine reviews 2007, 28(3):297. 10.1210/er.2006-0027, 17409287.
103. Eisen M, Spellman P, Brown P, Botstein D. Cluster analysis and display of genome-wide expression patterns. 1998, 95:14863-14868. National Acad Sciences.
104. Weinstein J, Myers T, O'Connor P, Friend S, Fornace A, Kohn K, Fojo T, Bates S, Rubinstein L, Anderson N. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275(5298):343. 10.1126/science.275.5298.343, 8994024.
105. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007, 8(8):R157. 10.1186/gb-2007-8-8-r157, 2374988, 17683518.
106. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, Harris L, Barnard N, Martel M, Levine AJ, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007, 67(22):10669-10676. 10.1158/0008-5472.CAN-07-0539, 18006808.